Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer

Squamous cancer of the lung (SQCC), although no longer the premier variant of non-small cell lung cancer, continues to impose a heavy world-wide burden. Advanced SQCC has enjoyed little of the recent progress benefiting patients with adenocarcinoma of the lung, but that has now begun to change. This...

Descripción completa

Detalles Bibliográficos
Autor principal: Vincent, Mark D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260675/
https://www.ncbi.nlm.nih.gov/pubmed/25538887
http://dx.doi.org/10.3389/fonc.2014.00320
_version_ 1782348205799768064
author Vincent, Mark D.
author_facet Vincent, Mark D.
author_sort Vincent, Mark D.
collection PubMed
description Squamous cancer of the lung (SQCC), although no longer the premier variant of non-small cell lung cancer, continues to impose a heavy world-wide burden. Advanced SQCC has enjoyed little of the recent progress benefiting patients with adenocarcinoma of the lung, but that has now begun to change. This article reviews the underlying molecular pathology of SQCC, as well as potential new targets and the corresponding novel targeted agents; included are some of which may soon be approvable in this notoriously hard-to-treat indication.
format Online
Article
Text
id pubmed-4260675
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-42606752014-12-23 Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer Vincent, Mark D. Front Oncol Oncology Squamous cancer of the lung (SQCC), although no longer the premier variant of non-small cell lung cancer, continues to impose a heavy world-wide burden. Advanced SQCC has enjoyed little of the recent progress benefiting patients with adenocarcinoma of the lung, but that has now begun to change. This article reviews the underlying molecular pathology of SQCC, as well as potential new targets and the corresponding novel targeted agents; included are some of which may soon be approvable in this notoriously hard-to-treat indication. Frontiers Media S.A. 2014-12-09 /pmc/articles/PMC4260675/ /pubmed/25538887 http://dx.doi.org/10.3389/fonc.2014.00320 Text en Copyright © 2014 Vincent. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Vincent, Mark D.
Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
title Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
title_full Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
title_fullStr Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
title_full_unstemmed Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
title_short Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
title_sort promising targets and current clinical trials in metastatic squamous cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260675/
https://www.ncbi.nlm.nih.gov/pubmed/25538887
http://dx.doi.org/10.3389/fonc.2014.00320
work_keys_str_mv AT vincentmarkd promisingtargetsandcurrentclinicaltrialsinmetastaticsquamouscelllungcancer

Ejemplares similares